

Human CellExp™ ErbB2 / HER2 / CD340, human recombinant

CATALOG #: 7397-10 10 µg

ALTERNATE NAMES: ERBB2, CD340, HER-2/neu, HER2, MLN19, NEU, NGL, TKR1

SOURCE: HEK 293 cells (Thr 23 - Thr 652)

PURITY: ≥ 95% by SDS-PAGE gel

MOL. WEIGHT: This protein is fused with polyhistidine tag at the C-terminus, has a calculated MW of 72.4 kDa. The predicted N-terminus is Thr 23. DTT-reduced Protein migrates as 90-110 kDa due to glycosylation.

ENDOTOXIN LEVEL: <1 EU/µg by LAL method

FORM: Lyophilized

FORMULATION: Lyophilized from 0.22 µm filtered solution in PBS, pH7.4. Generally 5-8% Mannitol or trehalose is added as a protectant before lyophilization.


STORAGE CONDITIONS: Store at -20°C. After reconstitution, aliquot and store at -20°C and use within 3 months. Avoid repeated freezing and thawing cycles.

RECONSTITUTION: Centrifuge the vial prior to opening. Reconstitute in sterile PBS, pH 7.4 to a concentration of 50 µg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 month. For extended storage, it is recommended to store at -20°C.

DESCRIPTION: Human Epidermal growth factor Receptor 2 (HER2) is also called ERBB2, HER-2, HER-2 /neu, NEU, NGL, TKR1 and c-erb B2, and is a protein giving higher aggressiveness in breast cancers. It is a member of the ErbB protein family, more commonly known as the epidermal growth factor receptor family. HER2 is a cell membrane surface-bound receptor tyrosine kinase and is normally involved in the signal transduction pathways leading to cell growth and differentiation. HER2 is thought to be an orphan receptor, with none of the EGF family of ligands able to activate it. Approximately 30% of breast cancers have an amplification of the HER2 gene or overexpression of its protein product. Overexpression of this receptor in breast cancer is associated with increased disease recurrence and worse prognosis. HER2 appears to play roles in

development, cancer, communication at the neuromuscular junction and regulation of cell growth and differentiation.

BIOLOGICAL ACTIVITY: Measured by its ability to block anti-ErbB2 mediated inhibition of SK-BR-3 human breast cancer cell proliferation. The ED₅₀ for this effect is typically 5-45 ng/ml in the presence of 0.6 µg/ml goat anti-hErbB2.



Human recombinant HER2/ErbB2

RELATED PRODUCTS:

- Human CellExp™ HER1/ErbB1, human recombinant (**Cat. No. 7396-10**)
- EGF Receptor, human recombinant (**Cat. No. 7135-10, -50**)
- ErbB4/HER4 (His Tagged), Human Recombinant (**Cat. No. 7773-5**)
- HER2, Active (**Cat. No. 7762-5, -100**)
- HER2/ErbB2 Antibody (**Cat. No. 3783-100**)

FOR RESEARCH USE ONLY! Not to be used in humans.